Once in a while, someone in San Francisco or in Sweden discovers a business model that is perfect for scaling. And if it works there, it will work everywhere. Existing players in the US (FH) have cracked the code, they've reached $400M ARR in less than 3 years by making preventative health testing accessible through a beautiful consumer experience.
Healthcare is having its "Nokia to iPhone moment" as consumers now want: Direct access to their health data, preventative rather than reactive care, beautiful, convenient experiences, and 24/7 personalized recommendations combined with AI.
Europe is ready, the underlying consumer needs, tech adoption, and health trends are the same. Many European founders assume their market is “too different.” Our conviction is the opposite: this is the next Spotify or Delivery Hero-type opportunity to replicate a proven model and scale it into a much larger, continent-wide leader. We will drive the execution.
This story is about recognizing a proven billion-dollar model and being the best to execute it globally before anyone else realizes the opportunity.
Medicine 3.0 is ready to spread worldwide
US players have started showing that replacing old healthcare (Medicine 2.0) can scale quickly. M 2.0 is reactive and misses "Four Horsemen" of chronic disease (heart disease, cancer, brain, metabolic). Medicine 3.0 is a rocket ship. Some of the fastest scaling companies in the history of health tech are moving in the US with subscriptions that are proactive, personalized, and data-driven; integrating biomarkers, sports science, AI, nutrition, and mental health for disease prevention.
We are taking it global. We have assembled a team of veteran startup builders and scalers to capture this opportunity in the dozens of countries where this model is waiting to be deployed, first in 4 European countries.
Axo Longevity is building Europe's first high-performance consumer health platform for this new era.
For decades, old healthcare has been reactive, designed to treat sickness after it appears. Medicine 2.0 has failed to stop the “Four Horsemen” of chronic disease: heart disease, cancer, neurodegeneration, and metabolic disorders, claiming ~41 million lives annually, including 17.9M from cardiovascular causes and 9M from neurological disease.
The ground is shifting under our feet. A global shift is underway. Medicine 3.0 is proactive, data-driven, and personalized, combining biometrics, sports science, AI, nutrition, and mental health to prevent disease before it starts.
Longevity is not a trend. It’s the convergence of technology, science, and mindset, a movement of people taking control of their health span because they refuse to rely on the broken old system.
Axo Longevity is building Europe’s first high-performance longevity platform for this new era.
Axo Longevity’s mission is to unlock top human performance and extend health span for everyone. We start at the top, serving those on the bleeding edge of performance, because they demand the highest standards and generate the most valuable data. This high-performance wedge is our entry point to build trust, brand authority, and a unique dataset. Then we scale down the mountain, giving every person access to the same tools, insights, and science once reserved for champions.
Together with LifeX.Ventures, we have identified a major opportunity to reinvent proactive health and performance in the U.S., a model now expanding across Europe, Latin America, the Middle East, and Japan. Axo Longevity is one of several platforms we’re building to meet this global demand.
Axo Longevity is poised to revolutionize health and performance in Europe by offering a high-performance health/wellness membership targeting pro and amateur athletes, biohackers, top tier professionals, founders and people on the bleeding edge of human performance.
This model already works for consumers in the U.S., as shown by Function Health, and Superpower’s rapid growth. Europe is ready, the underlying consumer needs, tech adoption, and health trends are the same. Many European founders assume their market is “too different.” Our conviction is the opposite: this is the next Spotify or Delivery Hero-type opportunity to replicate a proven model and scale it into a much larger, continent-wide leader.